Entropy Neurodynamics released early Phase 2 data showing 12-week symptom improvements for binge eating disorder using an experimental psilocin infusion.
On September 14, 2026, PharmaDispatch reported early clinical trial results from Entropy Neurodynamics. The Australian clinical-stage biotechnology company released data on an experimental intravenous psilocin candidate called TRP-8803. This Phase 2 trial focused on six individuals suffering from treatment-resistant binge eating disorder. These participants received two treatment sessions and reportedly maintained symptom improvements three months after their final infusion.
The clinical findings are being generated in collaboration with Swinburne University of Technology. This small study highlights an increasing clinical interest in targeting the neurobiological roots of compulsive behaviors.
Compulsive eating is increasingly understood as a deeply ingrained biological challenge. It is not simply a failure of personal discipline. Researchers are actively investigating whether tightly supervised neurobiological interventions can produce lasting changes in eating symptoms. Entropy reported that its first cohort demonstrated reproducible changes in brain dynamics alongside substantial clinical improvement.
TRP-8803 is an intravenously infused form of psilocin. Psilocin serves as the active metabolite of psilocybin. Entropy has designed this specific delivery method to address several common limitations of oral psychedelic formulations.
By administering the compound intravenously, researchers can tightly control the onset and depth of the patient experience. They can also manage the overall duration and time commitment required for the therapeutic session. This high level of control is highly relevant when addressing complex conditions like treatment-resistant binge eating disorder. It allows medical staff to regulate the treatment process directly.
The broader clinical program for Entropy Neurodynamics includes a 72-patient development program spanning eight different indications. TRP-8803 currently serves as the lead program specifically targeting treatment-resistant binge eating disorder. The company is simultaneously developing a separate oral psilocybin formulation known as TRP-8802. This oral candidate is being studied for conditions that include fibromyalgia and irritable bowel syndrome.
Understanding the biological drivers of hunger and habits is crucial for sustainable health. For those working to replace refined carbs with pulses to blunt insulin responses, brain health and metabolic function go hand in hand.
Mainstream coverage of emerging psychedelic medicine often leans toward sensationalism. It is critical to view these specific findings strictly as an early signal rather than established medical science. The available reporting does not feature a peer-reviewed publication or an independent investigator quotation. These statistics represent company-reported Phase 2 findings from an exceptionally small group of participants.
Furthermore, the reported cohort lacked any control group in the available source material. Because there was no randomized comparator, these results cannot definitively prove that TRP-8803 directly caused the symptom improvements. The reported benefits could be influenced by the highly structured clinical monitoring, therapeutic contact, or natural symptom fluctuations. Percentages can shift dramatically in a group of only six people.
Entropy used the phrase "full clinical remission" to describe three participants having no binge episodes during follow-up. Readers must avoid treating this promotional terminology as proof of a permanent recovery. Another significant reality check involves the sheer intensity of the treatment itself. Entropy reported that the subjective psychedelic experience was extremely intense for participants.
Nine of the 12 total infusions reached a maximum intensity rating of 10 out of 10. The mean peak intensity was recorded at a very high 9.4 out of 10. A treatment that is this intense could face serious practical barriers regarding supervision and tolerability.
Finally, these findings do not establish any body composition benefits or improvements in metabolic disease. The trial was exclusively focused on binge eating behaviors, mood symptoms, and quality of life. Readers seeking a sustainable path forward should separate binge-eating treatment from weight-loss goals. Just as a clear understanding of overeating and emotional eating requires targeted psychological support, treating clinical binge eating requires comprehensive medical guidance.
Despite the limitations of a six-person trial, the 12-week clinical observations offer a baseline for future neurobiological research. Entropy reported that all six participants maintained a clinically meaningful improvement in their symptoms through 12 weeks of follow-up. Weekly binge-eating episodes remained 73 percent below the pretreatment baseline at the 12-week mark. This reduction held relatively steady compared to a 74 percent reduction noted during the four-week assessment.
The durability of this early response is a primary focus for clinical researchers. Three of the six participants reported no binge-eating episodes at all during the 84-day follow-up window. This means 50 percent of the cohort experienced a complete cessation of binge episodes for three straight months. This metric is notable because the benefits extended well beyond the acute treatment sessions.
However, a 12-week follow-up does not establish durability beyond that three-month window. The company also tracked secondary outcomes related to participant mood and general well-being. The 12-week data showed a 50 percent reduction in anxiety and a 42 percent reduction in depression. Participants also reported a 61 percent improvement in their overall quality of life.
In terms of structured clinical assessment, clinician-rated Clinical Global Impression scores improved steadily. The scores moved from a 33 percent improvement at four weeks to a 44 percent improvement at 12 weeks. These metrics highlight a crucial point about measuring sustainable health outcomes. Success in this specific trial was defined entirely by reductions in anxiety and compulsive behavior frequency.
The results present no evidence that the intervention produces weight loss or replaces standard nutrition care. Treating complex behaviors often means looking far beyond the scale. Readers can see similar principles when examining how structured eating windows offer sustainable weight control by addressing daily meal timing rather than just absolute calories.
The next step for this clinical program involves testing the efficiency and scalability of the treatment. The first cohort utilized two lengthy 140-minute infusion sessions per participant. Entropy now plans to test a much shorter protocol for its next trial group. Cohort 2 will evaluate two 60-minute sessions, with topline results expected in the fourth quarter of 2026.
This protocol change demonstrates that reducing the time commitment of psychedelic therapy is an active development question. Reducing the session length is a significant variable for clinical researchers to navigate. A shorter infusion could meaningfully alter the intensity, tolerability, and clinical outcomes of the therapy. The results observed in the first cohort cannot be automatically generalized to this new abbreviated protocol.
Future protocols must be rigorously assessed for safety, accessibility, and ongoing psychological support. Researchers need to ensure that benefits remain after the structured treatment environment completely ends. Evidence from other psychedelic studies may support broader scientific interest in the field. However, it is not direct evidence for treating treatment-resistant binge eating disorder.
Wider reviews of psychedelic-assisted therapy show that the field remains in its early stages. A 2026 systematic review of treatments for substance-use disorders noted that larger controlled trials and active comparators are still needed. The review also called for a closer examination of the underlying psychotherapeutic mechanisms. Until larger studies confirm these early signals, adults dealing with persistent compulsive eating should consult qualified clinicians. Evidence-based treatments for mood symptoms and eating patterns remain the most practical and reliable options today.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
